Insights
Articles
Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard
Posted by Vikram Anand, Brandyn Abbott, Emily Becker, Nina Patel Lahanis, Larry Davis, PharmD on October 1, 202010/1/20
In their latest white paper, the Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful…
WODC 2020 Insights: Innovative Value and Access Strategies
Innovative rare disease therapies deserve innovative value and access strategies. With over 1,500 attendees from 50+ countries, the World Orphan Drug Congress featured four days of education, conversation and brainstorming dedicated to drug development and commercialization.…
The Evolving World of Artificial Intelligence: Rare Disease Impact
In his latest white paper, Oodaye Shukla, EVERSANA’s Chief Data and Analytics Officer, outlines the revolutionary impact that artificial intelligence and machine learning can have on improving patient outcomes and access to therapy. Rare disease statistics:…
The Regulatory Landscape in Digital Health
Despite the advances in digital health and digital therapeutics in recent years, there remains an ambiguity in the digital space and uncertainty surrounding regulation and reimbursement of digital technologies applied to pharma, biopharma and medical device…
Accelerating Rare Liver Disease Study Enrollment
An emerging clinical stage biotech contracted with EVERSANA to conduct Phase II trial enrollment support for an ultra-rare liver disease through our Seeker Health platform. Because of the ultra-rare patient population and nature of the therapy,…
Targeted Digital Patient Engagement
As the patient point of care continues to change and evolve, EVERSANA has identified challenges facing how we interact with patients, and how these challenges will impact patient engagement now and in the future. Supporting patients…
Patient Engagement During the COVID-19 Pandemic
As the public health pandemic spreads, EVERSANA has identified challenges facing clinical trial participation, and how these challenges will impact patients now and following the COVID-19 pandemic. […] Supporting patients and providing them with valuable information…
Clinical Pathways and Policy to Guard Against Misaligned Incentives
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization and underutilization. Moving forward, the more diligent payers…
[Infographic] Defining the Digital Space
Despite the increased popularity of Digital Therapeutics and Digital Medicines, there is still ambiguity around their definitions. This infographic provides clarity and defines the Digital Healthcare Space. Digital Therapeutics (DTx) Evidence-based digital solutions making direct therapeutic…
What does the new FDA Guidance for DTx Products Treating Psychiatric Disorders actually mean?
On April 14, 2020, FDA posted new guidance that eases regulatory enforcement of Digital Therapeutics to improve patient access to psychiatric care during the COVID-19 public health emergency. FDA should be praised for this decision, as…